4/5-Cognitive Neuroscience Task Reliability & Clinical Applications Consortium

4/5-认知神经科学任务可靠性

• 批准号: 7847800
• 负责人: James M. Gold
• 金额: $ 29.81万
• 依托单位: UNIVERSITY OF MARYLAND BALTIMORE
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-07-01 至 2012-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7847800
• 关键词: Activities of Daily Living; Address; Adverse effects; Aging; Area; Awareness; Basic Science; Behavioral; Behavioral Paradigm; Biocompatible Materials; Bioinformatics; Biological; Biological Markers; Brain; Brain imaging; Characteristics; Clinical; Clinical Investigator; Clinical Trials; Clinical assessments; Cognition; Cognitive; Cognitive deficits; Collaborations; Computer Systems; Consensus; Data; Data Analyses; Data Storage and Retrieval; Development; Ensure; Equipment; Evaluation; Explosion; Floor; Functional Imaging; Functional Magnetic Resonance Imaging; Funding; Genetic Polymorphism; Goals; Healthcare; Hour; Human; Image; Image Analysis; Impaired cognition; Individual; Individual Differences; Intervention; Knowledge; Lead; Length; Letters; Life; Linear Models; Literature; Maintenance; Measurement; Measures; Mediator of activation protein; Mental disorders; Methods; Modeling; Modification; Multi-Institutional Clinical Trial; National Institute of Mental Health; Neurosciences Research; Occupations; Outcome; Parents; Patients; Pattern; Perception; Performance; Persons; Pharmaceutical Preparations; Positioning Attribute; Principal Component Analysis; Process; Property; Psychometrics; Recording of previous events; Recruitment Activity; Research; Research Infrastructure; Retrieval; Sampling; Schizophrenia; Series; Signal Transduction; Site; Standardization; Stimulus; System; Task Performances; Testing; Time; Training; Translating; Translation Process; Translations; Universities; Validation; Visual; Washington; Work; base; clinical application; cognitive function; cognitive neuroscience; college; design; drug development; effective therapy; experience; functional outcomes; imaging modality; improved; independent component analysis; indexing; interest; meetings; member; neuroimaging; process optimization; public health relevance; relating to nervous system; response; skills; success; symposium; theories; therapy design; treatment effect; treatment response; visual control

DESCRIPTION (provided by applicant): This is a competitive revision in response to NOT-OD-09-058, the ARRA call for Competitive Supplement Applications. In the past decade there has been a growing awareness of the disabling effects of impaired cognition in individuals with schizophrenia and the importance of developing new treatments that target cognitive deficits. During this same period, the cognitive neuroscience field has seen an explosion of new knowledge regarding the neural basis of cognition. The application of this new knowledge to drug development in schizophrenia has lagged significantly behind overall progress in cognitive neuroscience, in large part due to the lack of data on the measurement properties of tasks used in cognitive neuroscience. This concern led to the Cognitive Neuroscience Research To Improve Cognition in Schizophrenia (CNTRICS) initiative, which conducted a series of conferences designed to develop consensus on the constructs and paradigms from cognitive neuroscience that are ripe for translation for use in clinical trials contexts. We were recently funded to start this translation process (Cognitive Neuroscience Task Reliability & Clinical Applications (CNTRACs) Consortium.") for behavioral paradigms. We brought together a collaborative team that represents significant expertise from the many fields necessary for the success of this endeavor. We are focusing on four constructs that span both early (gain control and visual integration in perception) and higher-level (goal maintenance, relational encoding and retrieval) components of human cognitive processing. Is this competitive revision we will extend this work in a highly critical and significant direction that the field has identified as a growing need - the development of well validated, and reliable functional neuroimaging paradigms that can serve as biomarkers for predicting and assessing drug and intervention response to treatments designed to enhance cognition. This focus meets one of the key topic areas for Competitive Supplements identified by the NIMH, namely Biomaterials and Biological Measures for the Study of Mental Disorders, which includes "Systematically collecting and analyzing biological measures (e.g., genetic polymorphisms, brain imaging indexes), which could be used, also in combination with clinically derived variables, to identify predictors of outcome, moderators of treatment response and adverse effects, or mediators and patterns of treatment effects." The end goal for these expanded aims will be to provide the field with: 1) easy to use imaging paradigms of these three cognitive functions that: 2) have been optimized for use in a clinical trials context (efficient, reliable, robust); while 3) maintaining their validity as specific measures of the cognitive and neural processes of interest. We believe that it is feasible to complete this added Aim in the time frame of the ARRA announcement, given that we have an established infrastructure. This set of collaborative R01 proposals meet the goals of the ARRA stimulus by providing for funding for 9 new positions, 3 positions that would allow us to retain staff that would otherwise need to be let go, and 1 position that we can increase from part to full time. PUBLIC HEALTH RELEVANCE: This project has high relevance for public health by significantly improving our ability to translate paradigms developed into the basic cognitive neuroscience literature for use in clinical trials aimed at improving cognition in schizophrenia. Cognitive deficits in schizophrenia are a major predictor of functional outcome in this debilitating illness. Thus, we need to improve our methods for detecting and enhancing cognitive function in schizophrenia in order to help individuals with this illness lead more productive and fulfilling lives.

描述（由申请人提供）：这是针对非od -09-058的竞争性修订，ARRA要求竞争性补充申请。在过去的十年里，人们越来越意识到精神分裂症患者认知障碍的致残效应，以及开发针对认知缺陷的新疗法的重要性。在同一时期，认知神经科学领域出现了关于认知神经基础的新知识的爆炸式增长。这一新知识在精神分裂症药物开发中的应用远远落后于认知神经科学的整体进展，这在很大程度上是由于缺乏认知神经科学中使用的任务测量特性的数据。这种关注导致了认知神经科学研究以改善精神分裂症患者的认知（CNTRICS）倡议，该倡议组织了一系列会议，旨在就认知神经科学的结构和范式达成共识，这些结构和范式已经成熟，可以用于临床试验环境。我们最近得到资助开始这个翻译过程（认知神经科学任务可靠性和临床应用（CNTRACs）联盟）。对于行为范式。我们汇集了一个协作团队，代表了这一努力成功所必需的许多领域的重要专业知识。我们专注于四个结构，它们跨越了人类认知加工的早期（增益控制和感知中的视觉整合）和高级（目标维持，关系编码和检索）组件。在这个竞争性修订中，我们将把这项工作扩展到一个高度关键和重要的方向，该领域已经确定为一个日益增长的需求——开发经过验证的、可靠的功能神经成像范式，可以作为生物标志物来预测和评估药物和干预对旨在增强认知的治疗的反应。这一重点符合NIMH确定的竞争性补充的关键主题领域之一，即精神障碍研究的生物材料和生物测量，其中包括“系统地收集和分析生物测量（例如，遗传多态性，脑成像指数），这些测量可以使用，也可以与临床衍生变量相结合，以确定结果的预测因素，治疗反应和不良反应的调节因子。或治疗效果的介质和模式。”这些扩展目标的最终目标将是为该领域提供：1)易于使用的这三种认知功能的成像范式；2)已优化用于临床试验环境（高效，可靠，稳健）；同时保持其作为感兴趣的认知和神经过程的具体测量的有效性。鉴于我们已经建立了基础设施，我们相信在ARRA公告的时间框架内完成这一增加的Aim是可行的。这组协作R01提案通过为9个新职位提供资金来满足ARRA刺激计划的目标，其中3个职位将允许我们保留那些可能需要被解雇的员工，另外1个职位我们可以从兼职增加到全职。